SRPKIN-1

SRPKIN-1 is a covalent and irreversible SRPK1/2 inhibitor with IC 50 s of 35.6 and 98 nM, respectively. Anti-angiogenesis effect In Vitro SRPKIN-1 treatment at 200 nM (10, 50, 100, 200 nM, 16 hours) significantly reduces SR protein phosphorylation at the steady state with or without washout. ? SRPK-IN-1 potently converts VEGF from pro-angiogenic to anti-angiogenic isoform. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: Ba/F3 cells Concentration: 0-10000 nM Incubation Time: 72 h Result: Potently decreased the level of SR phosphorylation in a dose-dependent manner, leading to increased VEGF-A165b RNA as well as protein even at a dose of 200 nM. In Vivo SRPKIN-1 (50 nM, 300 nM,1 μL, 5 times) blocks angiogenesis in a CNV mouse model through VEGF alternative splicing . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Mice Dosage: 50 nM, 300 nM, 1 μL Administration: Intravitreal injection, 5 times Result: SRPKIN-1-treated mice is significantly suppressed in a dose-dependent manner based upon measurement of the CNV area . Form:Solid IC50& Target:IC50: 35.6 nM (SRPK1), 98 nM (SRPK2)

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet